Navigation Links
NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis
Date:12/17/2008

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid and p<0.05 for naproxcinod 375 mg bid). Naproxcinod is the first compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

A significantly lower proportion of patients on naproxcinod experienced an increase in SBP of 5 mmHg or more, compared to naproxen

Over the whole 13 week period the proportion of patients whose SBP increased by 5 mmHg or more was higher for naproxen 500 mg bid, as compared to naproxcinod 750 mg bid (p<0.001), naproxcinod 375 mg bid (p=0.013) and placebo (p<0.001).

Both naproxcinod doses showed a similar blood pressure profile to placebo, in contrast to naproxen which raised SBP (p<0.001)

There is a clear unmet medical need for a novel anti-inflammatory agent with no detrimental impact on blood pressure. COX-2 inhibitors and traditional non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen, are widely used for the symptomatic treatment of OA but can lead to the onset of new episodes of high blood pressure or worsening of pre-existing hypertension. Both doses of naproxcinod (375 and 750 mg bid) were similar to placebo, as indicated by one-sided 95% confidence intervals (CIs). In contrast, naproxen 500 mg bid raised SBP compared to placebo (p<0.001).

Garret FitzGerald, MD, Professor of Medicine and Pharmacology at the University of Pennsylvania School of Medicine, commented:
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1379

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
2. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
3. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
4. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
5. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
6. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
9. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
10. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
11. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... The Netherlands , April 1, 2015 /PRNewswire/ ... its ISO 13485 certificate for their 100% medical North ... medical device manufacturers throughout North America ... President of HealthLink Europe and HealthLink International: "We now ... in Europe and one in ...
(Date:4/1/2015)... LAVAL, Quebec , April 1, 2015 ... Salix "), a wholly owned subsidiary of Valeant Pharmaceuticals ... that it today provided a Notice of Fundamental Changes, ... Notice, Notice of Execution of Supplemental Indenture and Offer ... its 1.5% Convertible Senior Notes due 2019 (the " ...
(Date:4/1/2015)... April 1, 2015  New York College of Health ... Intellectual Properties portfolio with U.S. Patent #8,996,098 donated by ... patent represents a surgical instrument that allows surgeons to ... it were in the traditional format of a slide ... medical databases during surgery, thus providing the surgeon real ...
Breaking Medicine Technology:Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 2Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 3Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 4Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 5Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 6Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 7Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3
... June 22 Hanger Orthopedic Group, Inc. (NYSE: HGR ... acquisition of Dynamic Orthotics and Prosthetics of Texas , Nebraska Orthotic ...  The companies operate 10 offices with annual revenues of $14.0 million ... "These companies ...
... 22 Xoft, makers of Electronic Brachytherapy systems ... integration of its Axxent® Electronic Brachytherapy System at the ... fully comprehensive breast center exclusively dedicated to the prevention, ... Lotus Breast Center is the first comprehensive breast center ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 3
(Date:4/2/2015)... CA (PRWEB) April 02, 2015 Veale ... and now two digital billboards to its name, announces ... billboard in the Dixon/Sacramento area. Similar to the ... freeway in Rohnert Park, California, the addition means, in ... the much sought after tourist population traveling through ...
(Date:4/2/2015)... 2015 New York Dynamic Neuromuscular Rehabilitation ... time in New York City, a groundbreaking, conservative method ... stroke (or other types of neurological diseases that damage ... A stroke is considered a cerebrovascular accident (CVA) that ... tissue resulting in damage to the nerve cells. Damage ...
(Date:4/1/2015)... Alcohol Awareness Month , The National Council ... sponsoring Alcohol Awareness Month every April since 1987. ... understating of alcohol-related issues. During the month of ... and alcoholism. , For the Health of It: Early ... for Alcohol Awareness Month. During April, focus is ...
(Date:4/1/2015)... April 01, 2015 NTOCC today launches ... of care tools that seek to improve care transitions ... program, NTOCC hopes to bring light to tools or ... of care across the healthcare industry through the promotion ... advance collaborative patient-care. Following that vision, the Knowledge & ...
(Date:4/1/2015)... 2015 New Jersey Governor First ... First Spouses from across the country in sponsoring ... 2015, World Down Syndrome Day(WDSD), to increase awareness ... area of Down syndrome cognition research. , In ... Alaska, American Samoa, Arizona, California, Colorado, Delaware, Florida, ...
Breaking Medicine News(10 mins):Health News:Veale Outdoor Advertising State of the Art Digital Billboards Reach 12 Million in SF Bay Area 2Health News:Virtual Environment Treatment Available for the First Time in NYC for Patients with Stroke 2Health News:Narconon Arrowhead Releases Guide to Handling Alcoholism in the Family for Alcohol Awareness Month 2Health News:Narconon Arrowhead Releases Guide to Handling Alcoholism in the Family for Alcohol Awareness Month 3Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment 2
... University of North Carolina in Chapel Hill that was published ... suggests that two genes - C282Y and H63D, which are ... to an increased risk of developing colon cancer. For the ... out// of which, more than 400 already had colon cancer, ...
... at Trinity College, Dublin, Ireland, have found from a ... arterial stiffness after smoking even one cigarette in both ... effects of smoking on large artery properties in 185 ... years. 116 non-smokers// were compared with 41 chronic smokers ...
... Patients with damaged discs have traditionally been treated by removing ... to fuse two bones together. Now, an artificial disc which ... phase of trials. The phase one study that was recently ... first phase of trials patients// were randomized, with one having ...
... banned in 1962, is being reassessed to find out if ... forms of cancer and leprosy. The drug which is unlicensed ... a cure for morning// sickness. However, it was banned after ... ,The European Agency for the Evaluation of Medicinal Products (EMEA) ...
... that were known until now were chickenpox, ear infections, ... found that stroke is also among one of the ... A National Hospital's database analysis by Dr. Donna Ferriero, ... that four in 1000 newborns had a stroke. ...
... survey across England showed that many do not eat ... other serious diseases. The survey included nearly// 15,600 adults ... revealed by the study. ,The survey indicated that ... household income. Almost 40% of women in the highest ...
Cached Medicine News:Health News:Artificial discs available as replacements for damaged discs 2Health News:Stroke also in list of common childhood ailments 2
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... present with fever, sore throat, ... symptoms common with a viral ... able to distinguish these from ... is the one-step antibody test ...
... hCG urine/serum combo test that you can ... and faster results at the point-of-care ... 20 hCG is a rapid test for ... immunoassay technology to selectively detect elevated levels ...
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Medicine Products: